Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of entrectinib in the treatment of patients with pancreatic cancer.
It is important to identify which patients should receive this regimen, explains Pishvaian. There is a lot of controversy about whether molecular profiling should be done on patients with pancreatic cancer. Read more . . .